PMID- 23762097
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20211021
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2013
DP  - 2013
TI  - What are the molecules involved in regulatory T-cells induction by dendritic 
      cells in cancer?
PG  - 806025
LID - 10.1155/2013/806025 [doi]
LID - 806025
AB  - Dendritic cells (DCs) are essential for the maintenance of homeostasis in the 
      organism, and they do that by modulating lymphocyte priming, expansion, and 
      response patterns according to signals they receive from the environment. The 
      induction of suppressive lymphocytes by DCs is essential to hinder the 
      development of autoimmune diseases but can be reverted against homeostasis when 
      in the context of neoplasia. In this setting, the induction of suppressive or 
      regulatory T cells contributes to the establishment of a state of tolerance 
      towards the tumor, allowing it to grow unchecked by an otherwise functional 
      immune system. Besides affecting its local environment, tumor also has been 
      described as potent sources of anti-inflammatory/suppressive factors, which may 
      act systemically, generating defects in the differentiation and maturation of 
      immune cells, far beyond the immediate vicinity of the tumor mass. Cytokines, as 
      IL-10 and TGF-beta, as well as cell surface molecules like PD-L1 and ICOS seem to 
      be significantly involved in the redirection of DCs towards tolerance induction, 
      and recent data suggest that tumor cells may, indeed, modulate distinct DCs 
      subpopulations through the involvement of these molecules. It is to be expected 
      that the identification of such molecules should provide molecular targets for 
      more effective immunotherapeutic approaches to cancer.
FAU - Ramos, Rodrigo Nalio
AU  - Ramos RN
AD  - Department of Immunology, Institute of Biomedical Sciences, University of Sao 
      Paulo, Avenida Professor Lineu Prestes, 1730 Sao Paulo, SP, Brazil.
FAU - de Moraes, Cristiano Jacob
AU  - de Moraes CJ
FAU - Zelante, Bruna
AU  - Zelante B
FAU - Barbuto, Jose Alexandre M
AU  - Barbuto JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130522
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (ICOS protein, human)
RN  - 0 (Inducible T-Cell Co-Stimulator Protein)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - B7-H1 Antigen/genetics/*immunology
MH  - Cell Communication
MH  - Dendritic Cells/*immunology/pathology
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immune Tolerance
MH  - Inducible T-Cell Co-Stimulator Protein/genetics/*immunology
MH  - Interleukin-10/genetics/*immunology
MH  - Lymphocyte Activation
MH  - Neoplasms/*immunology/pathology
MH  - Signal Transduction
MH  - T-Lymphocytes, Regulatory/*immunology/pathology
MH  - Transforming Growth Factor beta/genetics/*immunology
MH  - Tumor Microenvironment/immunology
PMC - PMC3674660
EDAT- 2013/06/14 06:00
MHDA- 2013/12/16 06:00
PMCR- 2013/05/22
CRDT- 2013/06/14 06:00
PHST- 2013/02/28 00:00 [received]
PHST- 2013/04/22 00:00 [accepted]
PHST- 2013/06/14 06:00 [entrez]
PHST- 2013/06/14 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2013/05/22 00:00 [pmc-release]
AID - 10.1155/2013/806025 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2013;2013:806025. doi: 10.1155/2013/806025. Epub 2013 May 22.